Departments and Services | For Patients | Research & Trials | Education | Find a Doctor


Search:
Division of Infectious Disease
 
    
Division of Infections Disease
 
Home
Fellowship Program
Clinical Programs
Penn CDC Prevention Epicenters Program
Clinical Trials
Penn CFAR
Botswana-UPenn Partnership
Seminars
Faculty
Adjunct Faculty
Administrative Contacts
Outpatient Clinics
News

Faculty

faculty photo

Pablo Tebas, M.D.

Professor of Medicine at the Hospital of the University of Pennsylvania
Attending Physician, Hospital of the University of Pennsylvania
Director & Principal Investigator, AIDS Clinical Trial Unit (ACTU) research site, University of Pennsylvania
Investigator of the Vaccine Trials Network, University of Pennsylvania
Director, Developmental Core Center for AIDS research (CFAR), Perelman School of Medicine, University of Pennsylvania
Department: Medicine

Contact information
Academic Address: 502 Johnson Pavilion
Clinical Office: 4 Perelman Center for Advanced Medicine, 3600 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-349-8092
Fax: 215-349-8011
Education:
MD
Universidad Autónoma de Madrid, Spain, 1985.
Post-Graduate Training
Intern in Medicine, Hospital Puerta de Hierro, Madrid, Spain, 1986-1987.
Resident in Medicine, Hospital Puerta de Hierro, Madrid, Spain, 1987-1991.
Fellowship, Infectious Diseases, Washington University in Saint Louis, Missouri, 1992-1995.
Certifications
Spanish Board of Internal Medicine, 1992.
American Board of Internal Medicine, Internal Medicine, 2014.
American Board of Internal Medicine, Infectious Diseases, 2015.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

My research interests center around the study of the complications of HIV and its treatment, and currently in the evaluation of strategies for the cure of HIV infection.
I am the director and the PI of the AIDS clinical trial unit of the University of Pennsylvania.
I am one of the founding members of the HIV Reservoirs and Viral Eradication (Cure) Transformative Science Group (TSG) of the AIDS clinical trial group. In addition to my ACTG work, I am involved (as PI of the clinical project) in several early phase trials of new compounds developed in conjunction with the NIH in several IPCP grants, including a Phase I study evaluating the antiviral activity of aprepitant (an NK-1R antagonist that down-regulates the expression of CCR5), a phase I study evaluating the immunogenicity of a therapeutic DNA vaccine administered by intramuscular electroporation in collaboration with David Weiner and several gene therapy studies evaluating the therapeutic use of lentiviral vectors in the management of HIV infection (including the use of VIRxSYS 496 –antisense approach-, the first in humans Sangamo’s zinc finger nuclease for CCR5 edition, in collaboration with Dr. Carl June.

Description of Clinical Expertise

My clinical interest focus on the treatment of HIV infection and associated infections like hepatitis C. I have also a particular interest in the clinical manifestations and treatment of atypical mycobacterial infections. I also attend every year in the general infectious disease service of the hospital of University of Pennsylvania

Selected Publications

Jacobson, J. M., Zheng, L., Wilson, C. C., Tebas, P., Matining, R. M., Egan, M. A., Eldridge, J., Landay, A. L., Clifford, D. B., Luetkemeyer, A. F., Tiu, J., Martinez, A. L., Janik, J., Spitz, T. A., Hural, J., McElrath, J., Frahm, N., Actg A. Protocol Team: The Safety and Immunogenicity of an Interleukin-12-Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection. J Acquir Immune Defic Syndr 71(2): 163-71, February 2016.

Bedimo, R., Cutrell, J., Zhang, S., Drechsler, H., Gao, A., Brown, G., Farukhi, I., Castanon, R., Tebas, P., Maalouf, N. M.: Mechanisms of bone disease in HIV and hepatitis C virus: impact of bone turnover, tenofovir exposure, sex steroids and severity of liver disease. AIDS 30(4): 601-8, February 2016.

Wohl, D., Oka, S., Clumeck, N., Clarke, A., Brinson, C., Stephens, J., Tashima, K., Arribas, J. R., Rashbaum, B., Cheret, A., Brunetta, J., Mussini, C., Tebas, P., Sax, P. E., Cheng, A., Zhong, L., Callebaut, C., Das, M., Fordyce, M., Gs-Us- Study Team: A Randomized, Double-Blind comparison of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil fumarate (TDF), each coformulated with Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for initial HIV-1 Treatment: Week 96 results. J Acquir Immune Defic Syndr January 2016.

Gowda, C., McKittrick, N., Kim, D., Kappes, R. A., Lo Re, V., 3rd, Tebas, P.: Obesity Is Not Associated with Impaired Immune Response to Influenza Vaccination in HIV-Infected Persons. AIDS Res Treat 2015: 653840, December 2015.

Bedimo, R., Kang, M., Tebas, P., Overton, E. T., Hollabaugh, K., McComsey, G., Bhattacharya, D., Evans, C., Brown, T. T., Taiwo, B.: Effects of Pegylated Interferon/Ribavirin on Bone Turnover Markers in HIV/Hepatitis C Virus-Coinfected Patients. AIDS Res Hum Retroviruses November 2015.

Tebas, P., Kumar, P., Hicks, C., Granier, C., Wynne, B., Min, S., Pappa, K.: Greater change in bone turnover markers for efavirenz/emtricitabine/tenofovir disoproxil fumarate versus dolutegravir + abacavir/lamivudine in antiretroviral therapy-naive adults over 144 weeks. AIDS Septemeber 2015.

Naggie, S., Cooper, C., Saag, M., Workowski, K., Ruane, P., Towner, W. J., Marks, K., Luetkemeyer, A., Baden, R. P., Sax, P. E., Gane, E., Santana-Bagur, J., Stamm, L. M., Yang, J. C., German, P., Dvory-Sobol, H., Ni, L., Pang, P. S., McHutchison, J. G., Stedman, C. A., Morales-Ramirez, J. O., Brau, N., Jayaweera, D., Colson, A. E., Tebas, P., Wong, D. K., Dieterich, D., Sulkowski, M., I. O. N. Investigators: Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med 373(8): 705-13, August 2015.

Overton, E. T., Chan, E. S., Brown, T. T., Tebas, P., McComsey, G. A., Melbourne, K. M., Napoli, A., Hardin, W. R., Ribaudo, H. J., Yin, M. T.: Vitamin D and Calcium Attenuate Bone Loss With Antiretroviral Therapy Initiation: A Randomized Trial. Ann Intern Med 162(12): 815-24, June 2015.

Tebas, P., Spitsin, S., Barrett, J. S., Tuluc, F., Elci, O., Korelitz, J. J., Wagner, W., Winters, A., Kim, D., Catalano, R., Evans, D. L., Douglas, S. D.: Reduction of soluble CD163, substance P, programmed death 1 and inflammatory markers: phase 1B trial of aprepitant in HIV-1-infected adults. AIDS 29(8): 931-9, May 2015.

Morrow, M. P., Tebas, P., Yan, J., Ramirez, L., Slager, A., Kraynyak, K., Diehl, M., Shah, D., Khan, A., Lee, J., Boyer, J., Kim, J. J., Sardesai, N. Y., Weiner, D. B., Bagarazzi, M. L.: Synthetic consensus HIV-1 DNA induces potent cellular immune responses and synthesis of granzyme B, perforin in HIV infected individuals. Mol Ther 23(3): 591-601, March 2015.

back to top
Last updated: 08/30/2016
The Trustees of the University of Pennsylvania